Involvement of the CD39/CD73/adenosine pathway in T-cell proliferation and NK cell-mediated antibody-dependent cell cytotoxicity in Sézary syndrome-Reference-Cited by-同舟云学术

Involvement of the CD39/CD73/adenosine pathway in T-cell proliferation and NK cell-mediated antibody-dependent cell cytotoxicity in Sézary syndrome

Published:2022-04-28 Issue:17 Volume:139 Page:2712-2716
ISSN:0006-4971
Container-title:Blood
language:en
Short-container-title:

Author:

Sonigo Gabrielle¹²,Bozonnat Alizée¹²^ORCID,Dumont Maëlle¹²,Thonnart Nicolas¹²,Ram-Wolff Caroline¹²³,de Masson Adèle¹²³^ORCID,Bagot Martine¹²³,Bensussan Armand¹²^ORCID,Marie-Cardine Anne¹²

Affiliation:

1. INSERM U976, Team 1, Human Immunology, Pathophysiology, Immunotherapy, Paris, France;

2. Université de Paris, Saint Louis Research Institute, Paris, France; and

3. Department of Dermatology, Saint Louis Hospital, Assistance Publique-Hopitaux de Paris, Paris, France

Publisher

American Society of Hematology

Subject

Cell Biology,Hematology,Immunology,Biochemistry

Link

https://ashpublications.org/blood/article-pdf/139/17/2712/1894707/bloodbld2021014782.pdf

Reference19 articles.

1. The extracellular fluid of solid carcinomas contains immunosuppressive concentrations of adenosine;Blay;Cancer Res.,1997

2. The development and immunosuppressive functions of CD4(+) CD25(+) FoxP3(+) regulatory T cells are under influence of the adenosine-A2A adenosine receptor pathway;Ohta;Front Immunol.,2012

3. CD39 regulation and functions in T cells;Timperi;Int J Mol Sci.,2021

4. Targeting adenosine in cancer immunotherapy: a review of recent progress;Whiteside;Expert Rev Anticancer Ther.,2017

5. Blocking antibodies targeting the CD39/CD73 immunosuppressive pathway unleash immune responses in combination cancer therapies;Perrot;Cell Rep.,2019

Cited by 15 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Cutaneous T-cell lymphoma care across Europe: insights from the HORIZON programme;British Journal of Dermatology;2024-04-05

2. Purinergic pathways and their clinical use in the treatment of acute myeloid leukemia;Purinergic Signalling;2024-03-06

3. Advances in metabolic reprogramming of NK cells in the tumor microenvironment on the impact of NK therapy;Journal of Translational Medicine;2024-03-03

4. CD39 is expressed by a wide range of cutaneous T‐cell lymphomas;Skin Health and Disease;2024-01-10

5. Proteasome inhibitors reduce CD73 expression partly via decreasing p-ERK in NSCLC cells;Life Sciences;2023-11